雷卢戈利克斯用于转移性激素敏感前列腺癌与即将出现的
Prem Kumar1, Pragya Prem1, Raajul Jain2
1Department of Urology, Ranchi Urology Centre, Samford Hospital, Ranchi, Jharkhand, India.
Annals of African medicine
|September 9, 2025
概括
口服GnRH抗剂Relugolix在没有丸激素外科手术的情况下为晚期前列腺癌提供快速丸激素抑制. 这种口服选择在紧急转移性前列腺癌病例中提供症状缓解.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
背景情况:
- 晚期前列腺癌的氨化激素释放激素 (LHRH) 激动剂会导致丸激素激增和不足的卵泡刺激激素抑制,可能促进瘤生长.
- 可注射性淋巴激素释放激素 (GnRH) 抗剂可以避免激增,但具有诸如注射部位反应和每月服用等局限性.
- 口服GnRH抗剂Relugolix可以实现快速的抑制,没有爆发,并且已经证明降低了心血管风险.
研究的目的:
- 评估relugolix在治疗晚期前列腺癌中的有效性和安全性,特别是在紧急的临床场景中.
- 突出口服GnRH抗剂相对于传统的LHRH抗剂和注射性GnRH抗剂的优势.
主要方法:
- 一份病例报告,涉嫌患有转移性前列腺癌的72岁男性患者表现为严重的神经性疼痛和下肢虚弱.
- 在活检前启动relugolix,并配合佐列龙酸和类固醇.
主要成果:
- 患者在开始Relugolix的24小时内经历了显著的症状缓解.
- 在没有与LHRH激动剂相关的初始激增的情况下,实现了快速丸激素抑制.
结论:
- 瑞卢戈利克斯在对激素敏感转移性前列腺癌的紧急治疗中显示出有用性.
- 口服Relugolix为前列腺癌治疗提供了方便和有效的替代方案,有可能改善患者的治疗结果和生活质量.
相关概念视频
02:57Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84